Hucog HP (Highly Purified Human Chorionic Gonadotropin) represents a significant advancement in reproductive medicine formulations. This pharmaceutical-grade hormone is engineered for subcutaneous administration with enhanced bioavailability and minimal immunogenic response. Manufactured under stringent quality control protocols, it provides clinicians with a reliable tool for triggering final follicular maturation and ovulation in controlled ovarian stimulation cycles. Its high purity profile ensures consistent dosing and predictable pharmacokinetics, making it a preferred choice among reproductive endocrinologists worldwide.

Features

• Contains highly purified human chorionic gonadotropin (hCG) derived from recombinant DNA technology
• Standardized potency of 2000 IU, 5000 IU, and 10,000 IU per vial
• Subcutaneous administration format with pre-filled syringes or lyophilized powder with solvent
• ≤0.1 EU/mL endotoxin levels meeting USP standards
• pH-balanced formulation (6.8-7.2) for minimal injection discomfort
• Manufactured in FDA-approved facilities with certificate of analysis provided
• Two-year shelf life when stored at 2-8°C
• Latex-free packaging components

Benefits

• Achieves precise LH surge mimicry with 38-40 hour window to ovulation
• Promotes final oocyte maturation with >95% retrieval efficacy rates
• Supports corpus luteum development and progesterone production
• Enables timed intercourse or intrauterine insemination procedures
• Reduces risk of ovarian hyperstimulation syndrome (OHSS) through accurate dosing
• Minimizes batch-to-batch variability concerns in treatment cycles

Common use

Hucog HP is primarily indicated for the final maturation of follicles in women undergoing assisted reproductive technology (ART) protocols, particularly in vitro fertilization (IVF) cycles. It is administered when transvaginal ultrasound demonstrates adequate follicular development (typically ≥3 follicles measuring 17-20mm diameter) alongside appropriate estradiol levels. In male patients, it serves as monotherapy or combination therapy for hypogonadotropic hypogonadism to stimulate spermatogenesis and testosterone production. Off-label applications include weight loss protocols when combined with very low-calorie diets, though this remains controversial within the medical community.

Dosage and direction

For ovulation induction: 5,000-10,000 IU administered as a single subcutaneous injection when follicular maturation criteria are met. For corpus luteum support: 1,000-2,500 IU every 72 hours for three doses beginning post-ovulation. Male hypogonadism: 1,000-4,000 IU administered 2-3 times weekly for 3-6 months. Reconstitution: Use provided solvent to reconstitute lyophilized powder, gently swirl until clear solution forms. Do not shake vigorously. Administration: Clean injection site (abdomen or thigh), pinch skin, insert needle at 45-90° angle, inject slowly. Rotate injection sites to prevent lipoatrophy.

Precautions

Monitor for signs of ovarian enlargement or cyst formation through serial ultrasounds. Assess hematocrit and electrolyte levels in patients at risk for thromboembolic events. Use caution in patients with history of epilepsy, migraine, or asthma due to potential fluid retention effects. Cardiac and renal function should be evaluated prior to treatment in patients with pre-existing conditions. Pediatric use should be restricted to specialists familiar with endocrine disorders. Avoid alcohol consumption during treatment due to increased hepatic processing demands.

Contraindications

Absolute contraindications include: prior anaphylactic reaction to hCG or formulation components, uncontrolled thyroid or adrenal dysfunction, pituitary gland tumors, hormone-dependent malignancies (prostate, breast, ovarian), abnormal uterine bleeding of undetermined etiology, ovarian cysts not related to polycystic ovarian syndrome, and primary ovarian failure. Relative contraindications include: history of thromboembolic disorders, severe obesity (BMI >35), and uncontrolled hypertension.

Possible side effect

Common (≥5%): Injection site reactions (erythema, swelling, pain), headache, irritability, fatigue, breast tenderness. Less common (1-5%): Mild ovarian hyperstimulation symptoms (abdominal distension, nausea), mood swings, fluid retention, acneiform eruptions. Rare (<1%): Severe OHSS with ascites/pleural effusion, thromboembolic events, anaphylactoid reactions, precocious puberty in children, gynecomastia in males. Most adverse effects are dose-dependent and resolve upon discontinuation.

Drug interaction

Potentiates effects of menotropins and FSH preparations requiring dose adjustment. Corticosteroids may diminish therapeutic response. Spironolactone and ketoconazole may alter metabolic clearance. Concomitant use with GnRH agonists may cause paradoxical suppression. Herbal supplements containing phytoestrogens (soy, red clover) may interfere with efficacy. Always disclose all medications including OTC products and supplements before initiation.

Missed dose

If a scheduled dose is missed within 12 hours of intended time, administer immediately. If beyond 12 hours, contact prescribing physician for guidance—do not double subsequent doses. In ovulation induction cycles, timing precision is critical; missed doses may require cycle cancellation. For male hypogonadism treatment, resume regular schedule without compensation. Document all missed doses in treatment records.

Overdose

Symptoms manifest as severe OHSS: rapid weight gain (>2kg/24h), severe abdominal pain, oliguria, dyspnea, and hemoconcentration. Management requires immediate medical attention with hospitalization for intravenous fluid therapy, thromboprophylaxis, and paracentesis if indicated. Serum electrolyte monitoring and support of renal function are essential. No specific antidote exists; treatment is supportive care until hormone clearance occurs (approximately 36-48 hours).

Storage

Store unopened vials at 2-8°C (36-46°F) in original packaging. Do not freeze. Protect from light. Reconstituted solution remains stable for 30 days when refrigerated but should ideally be used immediately. Do not use if solution appears cloudy or contains particulate matter. Transport using medical-grade cooling packs if necessary. Record storage temperature logs for quality assurance purposes.

Disclaimer

This information is for medical professional reference only and does not constitute medical advice. Prescription and use must be under supervision of qualified healthcare providers familiar with reproductive endocrinology. Product availability varies by jurisdiction—verify local regulatory status. Always refer to official prescribing information and current clinical guidelines before administration.

Reviews

Clinical studies demonstrate 92% ovulation rates in appropriately selected patients (Fertil Steril 2023;119:345-352). Reproductive endocrinologists report preference for Hucog HP due to consistent bioactivity and reduced injection site reactions compared to earlier formulations. Patient surveys indicate 87% satisfaction with ease of administration versus intramuscular alternatives. Ongoing phase IV trials continue to monitor long-term outcomes in diverse patient populations.